The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. ⋯ In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
-
Letter Randomized Controlled Trial
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
-
Letter Randomized Controlled Trial
Empagliflozin and Major Renal Outcomes in Heart Failure.
-
Randomized Controlled Trial Multicenter Study
Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder.
Experimental studies and small clinical trials have suggested that treatment with intranasal oxytocin may reduce social impairment in persons with autism spectrum disorder. Oxytocin has been administered in clinical practice to many children with autism spectrum disorder. ⋯ This placebo-controlled trial of intranasal oxytocin therapy in children and adolescents with autism spectrum disorder showed no significant between-group differences in the least-squares mean change from baseline on measures of social or cognitive functioning over a period of 24 weeks. (Funded by the National Institute of Child Health and Human Development; SOARS-B ClinicalTrials.gov number, NCT01944046.).
-
Randomized Controlled Trial Multicenter Study Comparative Study
Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
Cell-culture-derived influenza vaccines may enable a closer antigenic match to circulating strains of influenza virus by avoiding egg-adapted mutations. ⋯ IIV4c provided protection against influenza in healthy children and adolescents across seasons, regardless of previous influenza vaccination. (Funded by Seqirus; EudraCT number, 2016-002883-15; ClinicalTrials.gov number, NCT03165617.).